Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Provisional evidence
Company news sentiment
LLY news sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
35/100 evidence confidence
99% direct company focus
6 current stories across 3 publishers
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone52/100
→
Published 30-day score51/100
Latest source headline
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
finance.yahoo.com · 12 Aug 2026 11:30
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to LLY.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.512.
51/100
News scoreEarly balanced news score
35/100
Confidencethin evidence
99%/100
Company news6 company stories
87/100
Story agreement13/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence10
0.512 after freshness weightingSource breadth60
3 independent publishersCompany relevance99
share tied directly to this companyFreshness68
recency-weighted evidenceAgreement87
how closely stories agreePublisher mix53
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202645MXN 20245.01+1.7%
31 Jul 202651MXN 19900.0-4.4%
24 Jul 202651MXN 20820.85+0.4%
17 Jul 202653MXN 20736.24+0.1%
10 Jul 202651MXN 20708.48-1.5%
03 Jul 202651MXN 21029.0-0.5%
26 Jun 202650MXN 21142.75+10.4%
19 Jun 202651MXN 19148.82-2.6%
Provisional evidence
News subjects
What is shaping the score
Regulatory and legal523 stories · 50%
Market update503 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com424 stories · 67%
nasdaq.com671 stories · 17%
MarketBeat501 stories · 17%
Recurring subjects
Subjects appearing most often
Pharma4Clinical Trials3Biotech3Regulation2Fda Approval2Obesity Treatment1Net Income1Lawsuit1Healthcare1Financial Results1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
19 Jun50 neutral13 Aug 22:54
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 22:54 | 53 | +0 | 57/100 (-4) | 64 (-1) | Measured |
| 12 Aug 23:59 | 53 | -2 | 61/100 (+3) | 65 (+11) | Measured |
| 11 Aug 23:59 | 55 | +2 | 58/100 (+5) | 54 (+11) | Measured |
| 10 Aug 23:59 | 53 | +0 | 53/100 (+12) | 43 (+14) | Measured |
| 09 Aug 23:59 | 53 | +2 | 41/100 (0) | 29 (0) | Measured |
| 08 Aug 23:59 | 51 | +6 | 41/100 (+5) | 29 (-1) | Measured |
| 07 Aug 23:59 | 45 | -5 | 36/100 (+5) | 30 (+1) | Provisional |
| 05 Aug 23:59 | 50 | +0 | 31/100 (0) | 29 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
finance.yahoo.comDirect company coverageStored article
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro
Antibody Drug ConjugatesBiotechCancerClinical Trials
- Published
- 12 Aug 2026 11:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.7% · 1.5d old
- Duplicates
- 1 consolidated
#250Tone
finance.yahoo.comDirect company coverageStored article
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an
Clinical TrialsFda ApprovalHealthcarePharmaRegulation
- Published
- 12 Aug 2026 09:30
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 17% · 1.6d old
- Duplicates
- 1 consolidated
#350Tone
MarketBeatDirect company coverageScored from headlineSource lookup
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock
- Published
- 11 Aug 2026 21:19
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6% · 2.1d old
- Duplicates
- 1 consolidated
#435Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial
Clinical TrialsFinancial ResultsLawsuitNet IncomeObesity TreatmentPharma
- Published
- 11 Aug 2026 12:44
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 31.1% · 2.4d old
- Duplicates
- 1 consolidated
#550Tone
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Eli Lilly and Company
PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. "We are excited to expand our strategic work with Veeva by moving to Vault CRM," said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly.
BiotechCrmPharma
- Published
- 11 Aug 2026 11:03
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.7% · 2.5d old
- Duplicates
- 1 consolidated
#667Tone
nasdaq.comDirect company coverageStored article
Eli Lilly's Foundayo Wins UK Approval
(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data
BiotechDiabetesEarningsFda ApprovalPharmaRegulation
- Published
- 11 Aug 2026 07:30
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 35.6% · 2.6d old
- Duplicates
- 1 consolidated
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 85 older LLY headlines. Open one page at a time when you need them.
Open older archiveHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.